Sight Sciences to share results of Sahara RCT vs Restasis with Medicare/payers

Sight Sciences announced the publication in Clinical Ophthalmology of the six-month primary results from the SAHARA randomized controlled trial RCT .”We are extremely pleased to have the successful six-month results of the SAHARA RCT now published in a peer-reviewed journal. The data from this trial support our belief in the clinical efficacy of interventional eyelid procedures enabled by TearCare technology versus the most commonly prescribed dry eye therapeutic for meibomian gland dysfunction,” said Paul Badawi, Co-Founder and Chief Executive Officer of Sight Sciences. “We plan to now focus on sharing these results with Medicare and commercial payors as we pursue fair and reasonable reimbursed market access to our technology.” The data generated in the SAHARA RCT demonstrates that interventional eyelid procedures for dry eye disease enabled by TearCare technology were superior at all measured time points through 6 months to twice daily Restasis prescription eyedrops or Restasis for the improvement of tear break up time TBUT , the trial’s primary dry eye signs endpoint and a key measure of aqueous retention, tear stability and the tear film’s ability to protect the ocular surface. ” ..TearCare was also superior to Restasis in several other important objective signs of dry eye and delivered statistically significant and clinically meaningful improvements from baseline in all other measures that were at least as good as Restasis at all time points. SAHARA included 345 subjects at 19 sites in 11 states randomized 1:1 to either TearCare or Restasis. TearCare and Restasis delivered clinically comparable and statistically significant improvements at every time point measured in patient reported outcomes measured by Ocular Surface Disease Index OSDI scores, the trial’s primary symptoms endpoint.